Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma: Financial Health And COPD Market Impact 2024
04:05pm, Thursday, 24'th Aug 2023
Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash reserves and no immediate need for additional fin
Verona Pharma: Targeting The Large COPD Market
04:44pm, Tuesday, 08'th Aug 2023
Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for its primary drug candidate that is targeting the la
Verona Pharma plc. (VRNA) Q2 2023 Earnings Call Transcript
08:21am, Saturday, 05'th Aug 2023
Verona Pharma plc. (NASDAQ:VRNA ) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
02:00am, Wednesday, 26'th Jul 2023
LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirat
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
02:00am, Thursday, 20'th Jul 2023
LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirato
Verona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial Position
09:08am, Sunday, 28'th May 2023
Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market. T
Verona Pharma to Present at Jefferies Healthcare Conference
02:00am, Wednesday, 24'th May 2023
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview
Verona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug
06:51pm, Thursday, 18'th May 2023
Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the drug showed a 40% pooled reduction in the rate of e
Verona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript
10:11am, Saturday, 13'th May 2023
Verona Pharma plc (NASDAQ:VRNA ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Offi
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
02:00am, Tuesday, 02'nd May 2023
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
02:00am, Tuesday, 25'th Apr 2023
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respirat
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
01:22am, Sunday, 16'th Apr 2023
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients
02:31am, Monday, 27'th Mar 2023
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trial
7 Biotech Stocks That Could Be the Next Big Thing
11:44am, Wednesday, 15'th Mar 2023
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c
